- Home
- MHN vs LFCR Comparison
MHN vs LFCR Comparison
Compare MHN & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$7.61
Company Overview
Basic Information| Metric | MHN | LFCR |
|---|---|---|
| Founded | 1997 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 296.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MHN | LFCR |
|---|---|---|
| Price | $10.39 | $7.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 59.2K | ★ 167.2K |
| Earning Date | 01-01-0001 | 01-02-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $128,867,000.00 |
| Revenue This Year | N/A | $2.80 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.47 |
| 52 Week Low | $8.69 | $4.76 |
| 52 Week High | $10.81 | $8.85 |
Technical Indicators
Market Signals| Indicator | MHN | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 52.51 |
| Support Level | $10.23 | $7.50 |
| Resistance Level | $10.51 | $7.90 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 49.15 | 41.57 |
Price Performance
Historical Comparison MHN
LFCR
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.